Anaesthetic agent | Advantages | Disadvantages | Dosing |
---|---|---|---|
Fentanyl/fluanisone (Hypnormâ„¢)-based combination | Good analgesic effect | Cardiovascular and respiratory depression | 10 ml/kg (mouse), 2.7 ml/kg (rat) i.p. mixture Hypnormâ„¢/Hypnovelâ„¢ (midazolam)/water mixture (1:1:2 volume) (120 to 140 min sleep time)Hypnormâ„¢ top-up 0.3 ml/kg (mouse), 0.1ml/kg (rat) i.p. (30 to 40 min sleep time) |
 | Sedative | Poor muscle relaxation alone |  |
 | Possible to top-up for long-term anaesthesia | Risk of enterohepatic recirculation: relapse |  |
 | Reversal of sedative effect with buprenorphine to speeds up recovery time | Prolonged recovery time |  |
 |  | Hypersensitivity to noise |  |
Ketamine-based combination | Analgesic effects | Muscle rigidity +++ unless combined with other agents. | Ketamine + medetomidine 75 mg/kg + 0.5 to 1 mg/kg i.p.(Ketamine + xylazine 75 to 100 mg/kg)/(10mg/kg i.p.)(60 to 120 min sleep time ) (mouse and rats)Atipamezole 1mg/kg i.p. |
 | Light sedation | Increases intracranial pressure. |  |
 | Wide safety margin | Recovery often involved with ataxia and hyper responsiveness. |  |
 |  | Can increase blood pressure |  |
Alfaxalone (Alfaxan) | Minimal respiratory or CVS depression | Administration route i.v. (rodents, cats) or i.m. (primates) | 15 to 20mg/kg (mouse), 10 to 12mg/kg (rat) i.v.(10 to 15 min sleep time after bolus)0.25 to 0.75 mg/kg/min i.v. infusion (long term) |
 | Rapidly metabolised, repeated doses do not accumulate. |  |  |
 | Suitable for long-term anaesthesia in rodents |  |  |
Propofol (Rapinovet®, Diprivan®) | Rapidly metabolised, continuous infusion possible for long-term anaesthesia. | i.v. use only | 26 mg/kg (mouse), 10 to 12mg/kg (rat) i.v.(10 to 15 min sleep time after bolus)2 to 2.5 mg/kg/min i.v. infusion (long-term, mouse) 0.5 to 1 mg/kg/min i.v. infusion (long-term, rat) |
 |  | No analgesic properties |  |
 | Rapid recovery | Severe respiratory depression |  |
 | Can be used in animals with hepatic or renal impairment. | Apnoea can occur after i.v. bolus |  |
Barbiturates products | Sedative effect | No analgesic properties | Pentobarbitone, 40 to 50mg/kg i.p. (mouse) (120 to 180 min sleep) |
 | Good hypnotic effect | Severe respiratory depression and hypotensive |  |
 | Reasonable muscle relaxation | Easy to overdose | Thiopentone, 30 mg/kg i.v. 15 min sleep (rat) |
 |  | Metabolites accumulate with time |  |
 |  | Caustic substances (thiopentone only i.v. route) |  |
Chloral hydrate | Sedative effect | No analgesic properties | 300 to 400 mg/kg i.p. (1 to 2 h sleep time) (mouse and rats) |
 | Good hypnotic effect | Paralytic ileus noted in rats |  |
 | Minimal CVS and respiratory depression | Terminal/non-recovery work only |  |
α-Chloralose | Sedative effect | No analgesic properties | 50 to 60 mg/kg i.p. (rats), 120 mg/kg i.p. (mouse)(8 to 12 h for non-recovery only)50 mg/kg i.v. bolus followed by 25 to 40 mg/kg/h (rats) |
 | Good hypnotic effect | i.v. use only |  |
 | Suitable for long-term anaesthesia | Slow induction and recovery associated with involuntary excitement |  |
 | Minimal CVS and respiratory depression | Terminal/non-recovery work only |  |
Urethane | Suitable for long-term anaesthesia. | Carcinogenic: only allowed to be used with special justification | 0.8 to 1.3 g/kg i.p. (mouse and rats)Duration of action 8 to 10 h (non-recovery only) |
 | Minimal CVS and respiratory depression | Terminal/non-recovery work only |  |
Avertin® (tribromoethanol) | Wide safety margin | Local irritation/peritonitis | 0.015 ml/g body wt of 2.5% i.p. |
 | Good muscle relaxation | Handling and storage safety issues | 30 min; supplemental doses of anaesthesia: minimum of 1/2 of the initial dose up to 1 ml maximum volume per animal |
 | Rapid induction and recovery | Toxic effects |  |